Needham & Company LLC Reaffirms Buy Rating for Harmony Biosciences (NASDAQ:HRMY)

Harmony Biosciences (NASDAQ:HRMY – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at Needham & Company LLC in a research report issued on Tuesday, Benzinga reports. They presently have a $50.00 target price on the stock. Needham & Company LLC’s target price suggests a potential upside of 70.94% from the company’s […]

Related Keywords

China ,United States ,America ,Jeffrey Dierks ,China Universal Asset Management Co ,Needham Company ,Hedeker Wealth ,Oakworth Capital Inc ,Allspring Global Investments Holdings ,Prairiewood Capital ,Goldman Sachs Group ,Cantor Fitzgerald ,Harmony Biosciences Holdings Inc ,Securities Exchange Commission ,Harmony Biosciences ,Get Free Report ,Exchange Commission ,Universal Asset Management ,Global Investments Holdings ,Biosciences Holdings ,Harmony Biosciences Daily ,Nasdaq Hrmy ,Thrmy ,Medical ,Reiterated Rating ,Needham Company Llc ,